Stat3 as a Therapeutic Target for the Treatment of Psoriasis: A Clinical Feasibility Study with STA-21, a Stat3 Inhibitor
Puteti vedea rezultatele testului in cateva fotografii cu leziuni de psoriazis aici
http://www.nature.com/jid/journal/v131/n1/fig_tab/jid2010255f6.html#figure-title
Ken Miyoshi, Mikiro Takaishi, Kimiko Nakajima, Mitsunori Ikeda, Takashi Kanda, Masahito Tarutani, Tatsuo Iiyama, Naoki Asao, John DiGiovanni and Shigetoshi Sano
Efficacy of topical treatment with STA-21 on psoriatic lesions. (a) Psoriatic lesions of two patients during the course (patient 1, a 56-year-old man; patient 2, a 83-year-old man). Improvement of psoriasis lesions following application of STA-21 on the indicated days compared with vehicle controls (Vaseline). (b) Sum of clinical scores of baseline, 1 week, and 2 weeks of lesions from all eight patients allocated in this study. Black line, Vaseline control; red line, STA-21 treated. Five patients (patients 1–5), who showed >30% difference in the score decline after 2 weeks treatment with STA-21 compared with vehicle control, are considered to be responders based on the scores. Δ% Score decline in patients 1–8: 50, 38, 31, 35, 63, 0, 0, and 14, respectively. (c) Summary data for the mean of clinical score across all eight patients. Mean±SD percent of the initial score is shown. Compared with vehicle controls (black line), STA-21-treated lesions (red line) showed clinical improvement. * P=0.026 (<0.05) and 0.056 at days 7 and 14, respectively.
Niciun comentariu:
Trimiteți un comentariu